Laboratory Correlates for a Phase II Trial of Romidepsin in Cutaneous and Peripheral T-Cell Lymphoma

Since romidepsin has shown promise in the treatment of T-cell lymphomas, we evaluated molecular endpoints gathered from 61 patients enrolled on a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma at the National Institutes of Health. The endpoints included histone H3 acetylati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Bates, Susan E., Zhan, Zhirong, Steadman, Kenneth, Obrzut, Tomasz, Luchenko, Victoria, Frye, Robin, Robey, Robert W., Turner, Maria, Gardner, Erin R., Figg, William D., Steinberg, Seth M., Ling, Alex, Fojo, Tito, To, Kin Wah, Piekarz, Richard L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2009
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838427/
https://ncbi.nlm.nih.gov/pubmed/19874311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07954.x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg